No Link Seen Between GLP-1 Receptor Agonist Use and Thyroid Cancer
By Lori Solomon HealthDay Reporter
WEDNESDAY, Jan. 22, 2025 -- Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published online Jan. 16 in Thyroid.
Sarah M. Baxter, from Queen’s University Belfast in Northern Ireland, and colleagues investigated if GLP-1 RA use compared to use of dipeptidyl peptidase-4 inhibitors (DPP-4is) was associated with thyroid cancer risk in patients with type 2 diabetes. The analysis included 98,147 GLP-1 RA users and approximately 2.49 million DPP-4i users, with a median follow-up ranging from 1.8 to 3.0 years.
The researchers found that GLP-1 RA use was not associated with an increased risk for thyroid cancer (pooled weighted hazard ratio, 0.81; 95 percent confidence interval, 0.59 to 1.12) compared with use of DPP-4i. Among GLP-1 RA ever-users, there was no increased risk in thyroid cancer with an increasing cumulative dose of GLP-1 RA.
"In this large multisite study, utilizing data from six population-based databases, we found no evidence that GLP-1 RA use is associated with an increased risk of thyroid cancer with follow-up ranging from 1.8 to 3.0 years, providing some reassurance to patients and clinicians about the short-term safety of these drugs," the authors write. "Nevertheless, evidence was insufficient to rule out excess risk with long-term use, due to the short follow-up."
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Read this next
Metabolic Surgery May Be Beneficial in MASH-Related Cirrhosis, Obesity
MONDAY, Feb. 3, 2025 -- For patients with compensated metabolic dysfunction-associated steatohepatitis (MASH)-related cirrhosis and obesity, metabolic surgery is associated with a...
Micronutrient Deficiencies Seen in More Than 45 Percent With Type 2 Diabetes
THURSDAY, Jan. 30, 2025 -- More than 45 percent of patients with type 2 diabetes (T2D) have micronutrient deficiencies, with the most prevalent deficiency being vitamin D...
GLP-1 RAs Tied to Higher Thyroid Cancer Risk in First Year of Treatment
THURSDAY, Jan. 30, 2025 -- The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.